473 related articles for article (PubMed ID: 15815732)
21. Pathology of gastrointestinal stromal tumors.
Hirota S; Isozaki K
Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
[TBL] [Abstract][Full Text] [Related]
22. [Gastrointestinal stromal tumour: our experience].
Versaci A; Macrì A; Ieni A; Terranova M; Leonello G; Saladino E; Speciale G; Famulari C
Chir Ital; 2009; 61(2):161-9. PubMed ID: 19536989
[TBL] [Abstract][Full Text] [Related]
23. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
Wardelmann E; Merkelbach-Bruse S; Pauls K; Thomas N; Schildhaus HU; Heinicke T; Speidel N; Pietsch T; Buettner R; Pink D; Reichardt P; Hohenberger P
Clin Cancer Res; 2006 Mar; 12(6):1743-9. PubMed ID: 16551858
[TBL] [Abstract][Full Text] [Related]
24. [Gastrointestinal stromal tumors: a broad clinical spectrum from incidental -discovery to acute gastrointestinal bleeding].
Siewert E; Tietze L; Maintz C; Geier A; Dietrich CG; Matern S; Gartung C
Z Gastroenterol; 2004 Mar; 42(3):233-42. PubMed ID: 15022111
[TBL] [Abstract][Full Text] [Related]
25. A study of the postoperative course in cases of GIST of the stomach. The efficacy of imatinib in cases of recurrence.
Higashi D; Watanabe Y; Hirano K; Shimomura T; Egawa Y; Tomiyasu T; Ishibashi Y; Futami K; Maekawa T; Ota A; Oshige K; Iwashita A
Anticancer Res; 2009 Nov; 29(11):4893-6. PubMed ID: 20032453
[TBL] [Abstract][Full Text] [Related]
26. Imatinib in gastrointestinal stromal tumors.
Bakshi CA; Jain RA; Sastry PS; Sainani AR; Advani SH
J Assoc Physicians India; 2004 May; 52():403-9. PubMed ID: 15656032
[TBL] [Abstract][Full Text] [Related]
27. Effect of imatinib (STI571) on metastatic gastrointestinal stromal tumors: report of a case.
Ando Y; Tsunoda T; Beck Y; Takayama T; Tahara H
Surg Today; 2005; 35(2):157-60. PubMed ID: 15674500
[TBL] [Abstract][Full Text] [Related]
28. Does imatinib turn recurrent and/or metastasized gastrointestinal stromal tumors into a chronic disease? - single center experience.
Armbrust T; Sobotta M; Gunawan B; Füzesi L; Langer C; Cameron S; Ramadori G
Eur J Gastroenterol Hepatol; 2009 Jul; 21(7):819-23. PubMed ID: 19369884
[TBL] [Abstract][Full Text] [Related]
29. [Clinical experience of imatinib mesylate for metastatic or recurrent gastrointestinal stromal tumor].
Toyokawa T; Yamashita Y; Yamamoto A; Shimizu S; Inoue T; Kanazawa A; Tsukamoto T; Ikehara T; Nishiguchi Y
Gan To Kagaku Ryoho; 2014 Jan; 41(1):55-8. PubMed ID: 24423952
[TBL] [Abstract][Full Text] [Related]
30. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall.
Pauwels P; Debiec-Rychter M; Stul M; De Wever I; Van Oosterom AT; Sciot R
Histopathology; 2005 Jul; 47(1):41-7. PubMed ID: 15982322
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
Le Cesne A; Blay JY; Bui BN; Bouché O; Adenis A; Domont J; Cioffi A; Ray-Coquard I; Lassau N; Bonvalot S; Moussy A; Kinet JP; Hermine O
Eur J Cancer; 2010 May; 46(8):1344-51. PubMed ID: 20211560
[TBL] [Abstract][Full Text] [Related]
32. Gastrointestinal stromal tumors: a 7-year experience from a tertiary care hospital.
Lakshmi VA; Chacko RT; Kurian S
Indian J Pathol Microbiol; 2010; 53(4):628-33. PubMed ID: 21045382
[TBL] [Abstract][Full Text] [Related]
33. Treatment of gastrointestinal stromal tumor with imatinib mesylate: a retrospective single-center experience in Heidelberg.
Kasper B; Kallinowski B; Herrmann T; Lehnert T; Mechtersheimer G; Geer T; Ho AD; Egerer G
Dig Dis; 2006; 24(1-2):207-11. PubMed ID: 16699280
[TBL] [Abstract][Full Text] [Related]
34. Gastric GIST: a single institutional retrospective experience with surgical treatment for primary disease.
An JY; Choi MG; Noh JH; Sohn TS; Kang WK; Park CK; Kim S
Eur J Surg Oncol; 2007 Oct; 33(8):1030-5. PubMed ID: 17428635
[TBL] [Abstract][Full Text] [Related]
35. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
Blanke CD; Rankin C; Demetri GD; Ryan CW; von Mehren M; Benjamin RS; Raymond AK; Bramwell VH; Baker LH; Maki RG; Tanaka M; Hecht JR; Heinrich MC; Fletcher CD; Crowley JJ; Borden EC
J Clin Oncol; 2008 Feb; 26(4):626-32. PubMed ID: 18235122
[TBL] [Abstract][Full Text] [Related]
36. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
Krug LM; Crapanzano JP; Azzoli CG; Miller VA; Rizvi N; Gomez J; Kris MG; Pizzo B; Tyson L; Dunne M; Heelan RT
Cancer; 2005 May; 103(10):2128-31. PubMed ID: 15812822
[TBL] [Abstract][Full Text] [Related]
37. Gastric GISTs. Personal experience.
Mingolla GP; Riccio PA; Linguerri R; La Donna M; Zannelli M; Artuso S
Ann Ital Chir; 2007; 78(4):283-8; discussion 288-9. PubMed ID: 17990602
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.
Mussi C; Schildhaus HU; Gronchi A; Wardelmann E; Hohenberger P
Clin Cancer Res; 2008 Jul; 14(14):4550-5. PubMed ID: 18628470
[TBL] [Abstract][Full Text] [Related]
39. The safety profile of imatinib in CML and GIST: long-term considerations.
Thanopoulou E; Judson I
Arch Toxicol; 2012 Jan; 86(1):1-12. PubMed ID: 21717109
[TBL] [Abstract][Full Text] [Related]
40. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.
Rutkowski P; Nowecki Z; Nyckowski P; Dziewirski W; Grzesiakowska U; Nasierowska-Guttmejer A; Krawczyk M; Ruka W
J Surg Oncol; 2006 Mar; 93(4):304-11. PubMed ID: 16496358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
